Tag Archive for: Pharmaceuticals

NICE Recommends ublituximab (BRIUMVI®▼) as an Option for Treating Relapsing-Remitting Multiple Sclerosis (RRMS)

/in

London, UK, Barcelona, Spain and Düsseldorf, Germany – 5 December 2024 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces that the National Institute for Health and Care Excellence (NICE) in the UK has issued a positive recommendation for the use of ublituximab (150 mg concentrate […]

Read more

Rare Disease Day 2024 – Call for greater awareness of X-linked adrenoleukodystrophy and cerebral adrenoleukodystrophy

/in

Barcelona, Spain and Düsseldorf, Germany – 29 February, 2024 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, and Minoryx Therapeutics, a late stage biotech company focused on the development of therapies for orphan central nervous system disorders, reaffirm their commitment on Rare Disease Day […]

Read more

Update on Regulatory Review of leriglitazone in the EU

/in

A re-examination for cerebral adrenoleukodystrophy (cALD) will be requested following a negative CHMP opinion Barcelona, Spain and Düsseldorf, Germany – 26 January, 2024 – Minoryx Therapeutics, a late stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders and Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused […]

Read more

Novo Holdings to acquire Ellab

/in

Novo Holdings A/S, a leading global life sciences investor, today announced that it has agreed to acquire Ellab from EQT. Headquartered in Hillerød, Denmark, Ellab (“Ellab”) provides validation and monitoring solutions and services for biotech and pharmaceutical processes. Its solutions and services measure and document parameters such as temperature, pressure and carbon dioxide, which helps […]

Read more

Neuraxpharm expands its business in Southeast Europe

/in

Acquisition of Brain Therapeutics with operations in Greece, Cyprus and the Balkan countries Dusseldorf and Barcelona, March 8th, 2022 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), today announces the expansion of its business in Southeast Europe through the acquisition of Brain Therapeutics, a CNS-focused marketing and distribution […]

Read more